Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

ClinicalTrials.gov ID: NCT06773936

Public ClinicalTrials.gov record NCT06773936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Study identification

NCT ID: NCT06773936
Recruitment status: Enrolling by invitation
Study type: Interventional
Phase: Phase 2
Lead sponsor: SWOG Cancer Research Network; Network
Enrollment: 55 participants

Conditions and interventions

Conditions

Interventions

Induction Phase Drug
Maintenance Drug
Post-Remission Drug
Re-Induction Phase Drug

Drug

Eligibility (public fields only)

Age range: 60 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 14, 2026
Primary completion: Apr 30, 2029
Completion: Jun 30, 2033
Last update posted: May 5, 2026

2026 – 2033

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
UC Irvine Medical Center	Orange	California	92868	—
Northwell Health/Center for Advanced Medicine	Lake Success	New York	11042	—
University of Rochester Medical Center	Rochester	New York	14642	—
Duke University Medical Center	Durham	North Carolina	27710	—
University of Cincinnati Cancer Ctr-UC Medical Ctr	Cincinnati	Ohio	45267	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	—
Baptist Memorial Health Care	Memphis	Tennessee	38120	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06773936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2026 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06773936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →